FDA panel rebuffs Otsuka's tolvaptan

FDA's Cardiovascular and Renal Drugs Advisory Committee voted 9-6 on Monday that the overall risk/benefit profile of tolvaptan from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) does not support appro...